List view / Grid view
Gene Therapy is the introduction of normal genes into cells in place of missing or defective ones in order to correct genetic disorders.
Scientists have created what they believe is the first rat model of Down’s syndrome. The animal model shares features with human Down’s syndrome, which will allow for efficient testing of new therapies.
A next-generation spatial genomics technology has allowed scientists to link specific genes to complex tumour characteristics at a scale and resolution not previously possible.
Using CRISPR gene-editing technology, scientists have developed a vaccine designed to prevent infection by Leishmania major.
Researchers have been able to significantly reduce tumours in a pre-clinical model of a rare genetic lung disease.
An iPSC technology leader taps industry veteran to drive growth in cell therapy and drug discovery markets.
New pre-clinical research from the Université Laval Faculty of Medicine and CHU de Québec–Université Laval Research Centre showed genetically mutating human cells could avoid Alzheimer’s disease.
New research by the University of California, San Diego could provide a much simpler way to repair disease-causing mutations in RNA.
Researchers have shown that engineered bacterial genes coding for sodium ion channels could lead to novel gene therapies for electrical heart diseases.
Scientists in Japan have developed a credible heart cell model for arrhythmogenic cardiomyopathy and observed a positive response in the condition using PKP2 gene therapy.
The capability to edit genes has been transformative in opening therapeutic avenues for hitherto untreatable diseases and aiding biological insight. Scientists have now discovered a way to enhance this process using retrons, making the process more efficient and effective.
Whitepaper discusses strategies to optimize various factors that cause off-target events with Invitrogen™ TrueCut™ HiFi Cas9 Protein.
Researchers at Children’s National Hospital in the US have developed a promising new gene therapy for limb-girdle muscular dystrophy (LGMD) 2B.
With operations in over 100 countries worldwide, GenScript Biotech, an industry leader in biotechnology reagent services, has established a new UK office in the Oxford area to better connect with the UK biosciences sector.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
